New initiative aims to improve chronic kidney disease screening
- Elanco Animal Health Incorporated will reduce its Board of Directors to 11 members by the 2025 Annual Meeting, with several members, including John P. Bilbrey, not seeking re-election at the end of their terms.
- William F. Doyle has resigned from the Board effective immediately to enter into a research agreement with Elanco, focusing on innovative therapies for pets, including targeted gene therapy for chronic kidney disease.
- Elanco signed a research agreement with WEDterinary LLC to develop novel therapies for chronic kidney disease in pets, aiming to enhance pet healthcare through innovative technologies.
47 Articles
47 Articles

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets
GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders:
EsSalud Ica conducts preventive campaign for World Kidney Day
As part of activities for World Kidney Day, the EsSalud Ica Care Network carried out a preventive health campaign to raise public awareness of the importance of kidney care in order to avoid complications that could trigger chronic kidney disease, kidney cancer, transplants, among others.
Coverage Details
Bias Distribution
- 88% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage